Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731264 | 0.93 | MEN1 (0.44) | CYP2D6PDE4BKDM4E | |
| SCHEMBL728881 | 0.92 | MEN1 (0.43) | CYP2D6PDE4BKDM4E | |
| SCHEMBL728597 | 0.92 | PDE4B (0.42) | CYP2D6PDE4BSRC | |
| SCHEMBL730970 | 0.91 | PDE4B (0.51) | CYP2D6TSHRPDE4BSRC | |
| SCHEMBL730436 | 0.91 | PDE4B (0.51) | CYP2D6TSHRPDE4BSRC | |
| SCHEMBL729253 | 0.91 | PDE4B (0.51) | CYP2D6TSHRPDE4BSRC | |
| SCHEMBL730552 | 0.88 | PDE4B (0.50) | CYP2D6TSHRPDE4BSRC | |
| SCHEMBL12729827 | 0.86 | TSHR (0.48) | CYP2D6TSHRPDE4BSRCKDM4E | |
| SCHEMBL723600 | 0.85 | PDE4B (0.47) | PDE4B | |
| SCHEMBL728717 | 0.84 | PDE4B (0.46) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| EP-2467376-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Kalypsys, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8138205-B2 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | KALYPSYS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138205-B2 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | KALYPSYS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138205-B2 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | KALYPSYS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2011093924-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011093924-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CYP2D6 1778/4885TSHR 3957/4885PDE4B 2/4885 |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CYP2D6 1778/4885TSHR 3957/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.